on GENEURO SA (EPA:GNRO)
GeNeuro Announces Unanimous Approval of Resolutions at AGM
Geneva, Switzerland, June 14, 2024 – GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company, revealed that all resolutions proposed at its Annual General Meeting (AGM) held on June 12, 2024, have been unanimously approved. A significant 81.54% of the company’s share capital was represented at the meeting.
Key resolutions included approving the annual report and year-end accounts for 2023, re-electing the Chairman and all Board members, approving the maximum aggregate compensation for the Board and management for 2025, and re-electing PricewaterhouseCoopers, Geneva, as auditors. Detailed results are available on the company's website.
R. E.Copyright © 2024 FinanzWire, all reproduction and representation rights reserved. Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all GENEURO SA news